Consolidated Statements of Equity (Deficit) - USD ($) $ in Thousands	Total	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Noncontrolling Interest [Member]
Balance at Dec. 31, 2016	$ 2,261	$ 0	$ 4	$ 175,887	$ (172,034)	$ (1,596)
Balance (in shares) at Dec. 31, 2016		0	3,345,466
Stock-based compensation	3,409	$ 0	$ 0	3,409	0	0
Stock issued under "at-the-market" offering	6,346	$ 0	$ 0	6,346	0	0
Stock issued under "at-the-market" offering (in shares)		0	313,583
Stock issued for exercise of stock options	$ 166	$ 0	$ 0	166	0	0
Stock issued for exercise of stock options (in shares)	11,965	0	11,965
Series A preferred stock issue costs	$ (27)	$ 0	$ 0	(27)	0	0
Series A preferred stock dividends	(73)	0	0	0	(73)	0
Series A and B preferred stock beneficial conversion feature discount	0	0	0	6,889	(6,889)	0
Net Loss	(15,174)	0	0	0	(15,174)	0
Non-controlling interest	(318)	0	0	0	0	(318)
Balance at Dec. 31, 2017	(3,410)	$ 0	$ 4	192,670	(194,170)	(1,914)
Balance (in shares) at Dec. 31, 2017		0	3,671,014
Stock-based compensation	2,074	$ 0	$ 0	2,074	0	0
Stock issued under "at-the-market" offering	12,172	$ 0	$ 3	12,169	0	0
Stock issued under "at-the-market" offering (in shares)		0	3,534,982
Common stock and warrants issued to vendors	35	$ 0	$ 0	35	0	0
Common stock and warrants issued to vendors (in Shares)		0	50,000
Series A preferred stock dividends	(243)	$ 0	$ 0	0	(243)	0
Series A and B preferred stock beneficial conversion feature discount	0	9,161	0	0	(9,161)	0
Issuance of Common Stock, preferred Stock and Warrants in Units Offering, net of issuance costs	16,916	$ 641	$ 2	16,273	0	0
Issuance of Common Stock, preferred Stock and Warrants in Units Offering, net of issuance costs (in shares)		15,723	2,520,000
Issuance of SYN Biomics Stock	36	$ 0	$ 0	977	0	(941)
Conversion of Series B Preferred Stock to Common	0	$ (4,042)	$ 6	6,556	(2,520)	0
Conversion of Series B Preferred Stock to Common (in shares)		(6,562)	5,706,087
Net Loss	(13,367)	$ 0	$ 0	0	(13,367)	0
Non-controlling interest	(54)	0	0	0	0	(54)
Balance at Dec. 31, 2018	$ 14,159	$ 5,760	$ 15	$ 230,754	$ (219,461)	$ (2,909)
Balance (in shares) at Dec. 31, 2018		9,161	15,482,083